Table 3.
Open in new tab

Comparison of patients according to SARS-CoV-2 specific cell-mediated immunity

COVIFERON (–) (n =18)COVIFERON (+) (n=40)P value
Sex, female, n (%)13 (72%)28 (70%)0.86
Age, years, mean (SD)63.3 (13.4)61.1 (13.9)0.59
BMI, mean (SD)27.3 (4.8)28.9 (6.0)0.32
RA, n (%)10 (55.6%)29 (72.5%)0.2
Disease duration, years, mean (SD)7.9 (6.4)6.0 (4.4)0.19
Concurrent treatment (at sampling), n (%)
HCQ4 (22.2%)13 (32.5%)0.43
MTX5 (27.8%)9 (22.5%)0.66
MMF4 (22.2%)3 (7.5%)0.11
JAKi0 (0%)1 (2.5%)—
CYC0 (0%)1 (2.5%)—
Belimumab0 (0%)1 (2.5%)—
Glucocorticoids, n (%)12 (66.7%)21 (52.5%)0.31
Glucocorticods median dose, mg (IQR)5 (2.5–5)5 (3.25–5.5)
Patients with 4 vaccines, n (%)4 (22.2%)8 (20%)0.85
Lymphocyte count (cells/μL), mean (SD)1757 (620)1956 (824)0.36
RTX cycles, median (IQR)5.5 (3.75–10)4 (2–6)0.06
RTX cumulative dose, grams, median (IQR)11 (6.75–14.75)6 (4–10.75)0.019
Last vaccine to sampling, days, median (IQR)177 (111–220)180 (119–173)0.67
Last RTX infusion to sampling, days, median (IQR)174 (116–188)131 (108–173)0.04
Timing of last vaccine between RTX cycles, n (%)0.89
0–4 months10 (55.6%)23 (57.5%)
5–6 months8 (44.6%)17 (42.5%)
Previous COVID-19 (before sampling), n (%)1 (5.6%)9 (23.1%)0.1
COVID-19 infection (post sampling), n (%)8 (44.4%)12 (30%)0.28
Anti-spike IgG, U/ml, median (IQR)0 (0-17)9.9 (2.4-89)0.019
COVIFERON (–) (n =18)COVIFERON (+) (n=40)P value
Sex, female, n (%)13 (72%)28 (70%)0.86
Age, years, mean (SD)63.3 (13.4)61.1 (13.9)0.59
BMI, mean (SD)27.3 (4.8)28.9 (6.0)0.32
RA, n (%)10 (55.6%)29 (72.5%)0.2
Disease duration, years, mean (SD)7.9 (6.4)6.0 (4.4)0.19
Concurrent treatment (at sampling), n (%)
HCQ4 (22.2%)13 (32.5%)0.43
MTX5 (27.8%)9 (22.5%)0.66
MMF4 (22.2%)3 (7.5%)0.11
JAKi0 (0%)1 (2.5%)—
CYC0 (0%)1 (2.5%)—
Belimumab0 (0%)1 (2.5%)—
Glucocorticoids, n (%)12 (66.7%)21 (52.5%)0.31
Glucocorticods median dose, mg (IQR)5 (2.5–5)5 (3.25–5.5)
Patients with 4 vaccines, n (%)4 (22.2%)8 (20%)0.85
Lymphocyte count (cells/μL), mean (SD)1757 (620)1956 (824)0.36
RTX cycles, median (IQR)5.5 (3.75–10)4 (2–6)0.06
RTX cumulative dose, grams, median (IQR)11 (6.75–14.75)6 (4–10.75)0.019
Last vaccine to sampling, days, median (IQR)177 (111–220)180 (119–173)0.67
Last RTX infusion to sampling, days, median (IQR)174 (116–188)131 (108–173)0.04
Timing of last vaccine between RTX cycles, n (%)0.89
0–4 months10 (55.6%)23 (57.5%)
5–6 months8 (44.6%)17 (42.5%)
Previous COVID-19 (before sampling), n (%)1 (5.6%)9 (23.1%)0.1
COVID-19 infection (post sampling), n (%)8 (44.4%)12 (30%)0.28
Anti-spike IgG, U/ml, median (IQR)0 (0-17)9.9 (2.4-89)0.019
Table 3.
Open in new tab

Comparison of patients according to SARS-CoV-2 specific cell-mediated immunity

COVIFERON (–) (n =18)COVIFERON (+) (n=40)P value
Sex, female, n (%)13 (72%)28 (70%)0.86
Age, years, mean (SD)63.3 (13.4)61.1 (13.9)0.59
BMI, mean (SD)27.3 (4.8)28.9 (6.0)0.32
RA, n (%)10 (55.6%)29 (72.5%)0.2
Disease duration, years, mean (SD)7.9 (6.4)6.0 (4.4)0.19
Concurrent treatment (at sampling), n (%)
HCQ4 (22.2%)13 (32.5%)0.43
MTX5 (27.8%)9 (22.5%)0.66
MMF4 (22.2%)3 (7.5%)0.11
JAKi0 (0%)1 (2.5%)—
CYC0 (0%)1 (2.5%)—
Belimumab0 (0%)1 (2.5%)—
Glucocorticoids, n (%)12 (66.7%)21 (52.5%)0.31
Glucocorticods median dose, mg (IQR)5 (2.5–5)5 (3.25–5.5)
Patients with 4 vaccines, n (%)4 (22.2%)8 (20%)0.85
Lymphocyte count (cells/μL), mean (SD)1757 (620)1956 (824)0.36
RTX cycles, median (IQR)5.5 (3.75–10)4 (2–6)0.06
RTX cumulative dose, grams, median (IQR)11 (6.75–14.75)6 (4–10.75)0.019
Last vaccine to sampling, days, median (IQR)177 (111–220)180 (119–173)0.67
Last RTX infusion to sampling, days, median (IQR)174 (116–188)131 (108–173)0.04
Timing of last vaccine between RTX cycles, n (%)0.89
0–4 months10 (55.6%)23 (57.5%)
5–6 months8 (44.6%)17 (42.5%)
Previous COVID-19 (before sampling), n (%)1 (5.6%)9 (23.1%)0.1
COVID-19 infection (post sampling), n (%)8 (44.4%)12 (30%)0.28
Anti-spike IgG, U/ml, median (IQR)0 (0-17)9.9 (2.4-89)0.019
COVIFERON (–) (n =18)COVIFERON (+) (n=40)P value
Sex, female, n (%)13 (72%)28 (70%)0.86
Age, years, mean (SD)63.3 (13.4)61.1 (13.9)0.59
BMI, mean (SD)27.3 (4.8)28.9 (6.0)0.32
RA, n (%)10 (55.6%)29 (72.5%)0.2
Disease duration, years, mean (SD)7.9 (6.4)6.0 (4.4)0.19
Concurrent treatment (at sampling), n (%)
HCQ4 (22.2%)13 (32.5%)0.43
MTX5 (27.8%)9 (22.5%)0.66
MMF4 (22.2%)3 (7.5%)0.11
JAKi0 (0%)1 (2.5%)—
CYC0 (0%)1 (2.5%)—
Belimumab0 (0%)1 (2.5%)—
Glucocorticoids, n (%)12 (66.7%)21 (52.5%)0.31
Glucocorticods median dose, mg (IQR)5 (2.5–5)5 (3.25–5.5)
Patients with 4 vaccines, n (%)4 (22.2%)8 (20%)0.85
Lymphocyte count (cells/μL), mean (SD)1757 (620)1956 (824)0.36
RTX cycles, median (IQR)5.5 (3.75–10)4 (2–6)0.06
RTX cumulative dose, grams, median (IQR)11 (6.75–14.75)6 (4–10.75)0.019
Last vaccine to sampling, days, median (IQR)177 (111–220)180 (119–173)0.67
Last RTX infusion to sampling, days, median (IQR)174 (116–188)131 (108–173)0.04
Timing of last vaccine between RTX cycles, n (%)0.89
0–4 months10 (55.6%)23 (57.5%)
5–6 months8 (44.6%)17 (42.5%)
Previous COVID-19 (before sampling), n (%)1 (5.6%)9 (23.1%)0.1
COVID-19 infection (post sampling), n (%)8 (44.4%)12 (30%)0.28
Anti-spike IgG, U/ml, median (IQR)0 (0-17)9.9 (2.4-89)0.019
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close